Last updated: August 14, 2026
Clofarabine is a niche oncology injectable with a simple, established excipient profile. The U.S. reference product, Clolar, contains clofarabine at 1 mg/mL in an aqueous solution with sodium chloride and water for injection; hydrochloric acid and sodium hydroxide may be used for pH adjustment.[1] The strongest commercial opportunities are generic injectable supply, hospital-ready presentations, compounding-risk reduction, container-closure optimization, and regional supply agreements rather than novel excipient exclusivity.
What excipients are used in clofarabine injection?
The approved Clolar formulation is a preservative-free, single-dose intravenous solution.
| Formulation attribute |
Clolar specification |
| Active ingredient |
Clofarabine |
| Strength |
1 mg/mL |
| Route |
Intravenous infusion |
| Primary excipients |
Sodium chloride and water for injection |
| pH adjustment |
Hydrochloric acid and/or sodium hydroxide |
| Preservative |
None |
| Container |
Single-dose glass vial |
| Dilution fluids |
0.9% sodium chloride injection or 5% dextrose injection |
| Administration |
Intravenous infusion over approximately two hours |
| Target diluted concentration |
Approximately 0.15 to 0.4 mg/mL |
The formulation is isotonic or near-isotonic and does not rely on a surfactant, cosolvent, antioxidant, chelator, or complex buffering system. The label directs dilution before administration and requires handling under aseptic conditions.[1]
Why is the excipient system simple?
Clofarabine is a small, polar purine nucleoside analog that can be formulated as an aqueous injectable solution at a relatively low concentration. The product does not require lipid dispersion, particle-size control, lyophilization, or a high-solubilization excipient system.
The formulation strategy has four primary functions:
- Maintain clofarabine in solution.
- Control tonicity for intravenous use.
- Maintain an acidic pH range suitable for product stability.
- Minimize excipient-related toxicity in pediatric oncology patients.
The absence of preservatives is commercially relevant. Pediatric leukemia patients may be immunocompromised, and the product is administered in controlled hospital settings where single-dose packaging is practical.
What formulation risks affect clofarabine product development?
The central technical risk is chemical stability in an aqueous, acidic environment rather than physical instability.
Hydrolysis and degradation
Clofarabine contains a nucleoside structure with a sugar moiety and glycosidic bond. Hydrolytic degradation, pH-dependent degradation, and impurity formation must be assessed during formulation development. A generic manufacturer must demonstrate that its formulation has an impurity profile comparable to the reference product over the proposed shelf life.
The formulation should be evaluated across:
- Acidic, neutral, and mildly basic pH conditions.
- Long-term and accelerated storage.
- Light exposure.
- Freeze-thaw cycling.
- Dilution into sodium chloride and dextrose solutions.
- Contact with infusion bags, tubing, and filters.
- Low-fill and high-fill vial configurations.
Container-closure compatibility
The commercial product is supplied in a glass vial. A generic developer considering polymeric vials, prefilled syringes, or ready-to-use infusion bags would face additional extractables, leachables, adsorption, and permeability studies.
Potential risks include:
- Adsorption to polymeric surfaces.
- Leachables from elastomeric stoppers.
- Loss of potency at low concentrations after dilution.
- Particulate generation during repeated transfers.
- Interaction with plasticized tubing.
- Increased oxygen or moisture transmission in non-glass systems.
Glass remains the lowest-risk presentation for a conventional generic vial. Polymer containers may provide logistical advantages but would require a clear commercial benefit to justify the additional development burden.
What excipient strategy is most attractive for generic clofarabine?
The lowest-risk strategy is a compositionally similar aqueous formulation using sodium chloride and water for injection, with pH adjustment by hydrochloric acid or sodium hydroxide.
Base-case strategy
A practical generic formulation would retain:
- 1 mg/mL clofarabine.
- Sodium chloride as the tonicity agent.
- Water for injection.
- Acid or base for pH adjustment.
- Single-dose, preservative-free packaging.
- Glass vial and standard injectable closure.
This approach minimizes formulation differences, reduces clinical and regulatory complexity, and supports an abbreviated approval pathway. FDA’s parenteral product guidance generally favors excipients that are already used in approved injectable products at established levels.[2]
Differentiated strategy
A manufacturer could pursue differentiation through the presentation rather than a new excipient platform.
Potential options include:
| Product concept |
Commercial value |
Development burden |
| Standard 20 mL vial |
Low development risk |
Low |
| Smaller pediatric vial |
Reduces waste and dosing inefficiency |
Moderate |
| Ready-to-dilute vial with clearer labeling |
Reduces preparation errors |
Low to moderate |
| Premixed infusion bag |
Reduces pharmacy compounding |
High |
| Dual-chamber or automated reconstitution system |
Limited need for this product |
High |
| Prefilled syringe |
Potentially useful for small doses |
High |
| Low-sorption infusion-compatible package |
Supports dose recovery |
Moderate |
The commercial case for a ready-to-use bag is constrained by clofarabine’s small, specialized market. A premixed presentation could reduce pharmacy labor and preparation risk, but it would increase stability, shipping, packaging, and waste-management requirements.
What formulation patents protect clofarabine products?
The major historical intellectual-property protection for clofarabine centered on the active compound and its therapeutic use, not on a complex excipient platform.
The original clofarabine compound patent family dates to the 1990s. The principal U.S. compound protection expired before the current decade, subject to any applicable patent-term adjustment or extension. FDA approved Clolar in 2006, and its orphan-drug exclusivity period was separate from patent rights.[3][4]
The reference formulation’s use of sodium chloride and water for injection is technically conventional. These excipients are unlikely to support meaningful composition-of-matter exclusivity without a distinct, patentable concentration range, stability effect, container system, or manufacturing process.
Are method-of-use patents still a major barrier?
Method-of-use patents may have covered treatment of relapsed or refractory acute lymphoblastic leukemia and related hematologic malignancies. Their commercial value is limited where the core indication and orphan exclusivity periods have expired and where an ANDA applicant can rely on a permissible labeling strategy.
A generic applicant may seek approval using:
- A full label, if all relevant protections have expired.
- A section viii carve-out for protected indications.
- A Paragraph IV certification if an unexpired listed patent is challenged.
The current Orange Book listing, rather than the product label, controls the relevant listed-patent analysis for an ANDA.[5]
What is the FDA regulatory status of clofarabine?
FDA approved Clolar for pediatric patients aged 1 to 21 years with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens.[1] The approval was granted under the orphan-drug framework.
| FDA milestone |
Date or status |
| NDA approval for Clolar |
December 2006 |
| Original sponsor |
Genzyme Corporation |
| Current corporate owner of legacy Genzyme oncology assets |
Sanofi |
| Orphan exclusivity |
Expired |
| Pediatric exclusivity |
Historical period expired |
| Dosage form |
Intravenous injection |
| Regulatory pathway for competitors |
ANDA or 505(b)(2), depending on product design |
Clofarabine is a small molecule, so biosimilar regulation does not apply. The relevant competitive pathways are generic ANDA products and potentially differentiated 505(b)(2) products.
How many patents cover clofarabine today?
A definitive count depends on the jurisdiction, patent family, terminal disclaimers, patent-term adjustments, and the specific product being analyzed. The original compound protection is historical rather than a current commercial barrier. Any surviving relevant rights would more likely relate to a specific formulation, use, manufacturing process, or device than to the basic clofarabine molecule.
For commercial diligence, the most important distinctions are:
| IP category |
Relevance to a new clofarabine injection |
| Compound patent |
Historical barrier; generally expired |
| Basic aqueous formulation |
Low likelihood of meaningful current exclusivity |
| Specific concentration or pH range |
Requires claim-by-claim review |
| Stability or impurity-control process |
Possible, but design-around may be feasible |
| Method-of-use patent |
Depends on listed status and label strategy |
| Container or delivery device |
Relevant only to differentiated presentations |
| Manufacturing process |
Relevant if process claims are valid and difficult to design around |
No biosimilar patent litigation risk exists because clofarabine is not a biologic. Paragraph IV risk is more relevant to any remaining Orange Book-listed patent than to biosimilar competition.
Which companies are positioned in the clofarabine market?
Genzyme developed and commercialized Clolar, and Sanofi inherited the asset through its acquisition of Genzyme. The market is likely to be served through a combination of the originator product, generic injectable suppliers, hospital distributors, and specialty oncology channels.
The competitive landscape has several characteristics:
- Small patient population.
- Hospital-only administration.
- High clinical acuity.
- Limited opportunity for consumer branding.
- Demand concentrated in pediatric and young-adult oncology centers.
- Procurement sensitivity to shortages and reliable supply.
- Low tolerance for formulation changes that increase preparation risk.
The most credible entrants are established injectable manufacturers with oncology quality systems, sterile-fill capacity, and access to U.S. hospital channels. A company with no sterile manufacturing infrastructure would face a higher barrier than one with an existing portfolio of oncology injections.
What commercial opportunities exist for clofarabine excipients?
The excipient opportunity is primarily a supply-chain and formulation-services opportunity, not a proprietary excipient opportunity.
1. Generic formulation supply
Manufacturers can supply compendial sodium chloride, water for injection, elastomeric closures, and low-extractables packaging to clofarabine generic developers. The excipient bill of materials is simple, so price competition will be intense.
2. Pediatric dose optimization
Clofarabine dosing is weight- or body-surface-area-based. Pediatric centers may not use the full vial content, creating waste. Smaller vial sizes or multiple-fill configurations could improve dose utilization.
The commercial benefit depends on balancing:
- Lower residual drug waste.
- More inventory-keeping units.
- Increased packaging and validation costs.
- Hospital purchasing preferences.
- Stability after vial entry.
3. Pharmacy-compounding reduction
A ready-to-dilute or premixed product could reduce manipulation in hospital pharmacies. This is attractive where oncology preparation capacity is constrained or where institutions prioritize closed-system handling.
The principal commercial risk is demand fragmentation. A small market may not support the additional manufacturing complexity of multiple premixed strengths.
4. Container-closure and delivery systems
Low-sorption bags, compatible tubing, and optimized stoppers could provide a modest product advantage. Any claim of improved dose recovery would require comparative testing under actual administration conditions.
5. Regional supply and shortage resilience
Clofarabine’s commercial value may rise during supply interruptions because treatment options for relapsed pediatric acute lymphoblastic leukemia are limited. A supplier with dual sterile sites, validated alternate component suppliers, and reliable hospital distribution could win contracts even without an innovative formulation.
How does clofarabine compare with competing leukemia drugs?
Clofarabine competes with other salvage therapies rather than with a single direct substitute. Relevant alternatives include nelarabine, blinatumomab, inotuzumab ozogamicin, intensive chemotherapy regimens, and hematopoietic stem-cell transplantation, depending on disease subtype and treatment history.
| Product |
Modality |
Biosimilar issue |
Formulation complexity |
Commercial implication |
| Clofarabine |
Small-molecule injectable |
None |
Low |
Generic price pressure |
| Nelarabine |
Small-molecule injectable |
None |
Low to moderate |
Competes in T-cell disease |
| Blinatumomab |
Biologic infusion product |
Biosimilar potential |
High |
Greater device and handling differentiation |
| Inotuzumab ozogamicin |
Antibody-drug conjugate |
Biosimilar complexity |
High |
Higher manufacturing barrier |
| Conventional chemotherapy |
Small molecules and combinations |
Varies |
Varies |
Procurement and regimen substitution |
Clofarabine’s low formulation complexity makes it easier to copy than biologic or antibody-drug conjugate products. Its value lies in clinical positioning, supply reliability, and hospital access.
What generic launch risks exist for clofarabine?
The main risks are regulatory equivalence, sterile manufacturing, market size, and clinical substitution.
A generic developer should expect scrutiny of:
- Injectable sameness and inactive ingredients.
- pH and osmolality.
- Particulate and sterility controls.
- Degradation products.
- Dilution stability.
- Compatibility with administration materials.
- Container-closure integrity.
- Labeling differences and indication carve-outs.
- Batch-to-batch impurity consistency.
The market may support only a limited number of sustainable suppliers. A low-price launch can be commercially unattractive if annual demand is small and sterile manufacturing costs remain fixed.
How strong is the clofarabine patent estate?
The estate is stronger historically than prospectively. Compound protection created the main exclusivity barrier, but that protection has expired. The basic formulation is conventional and offers limited room for broad, defensible claims.
The strongest potential IP positions would involve:
- A demonstrably superior stability profile.
- A specific impurity-control process.
- A novel ready-to-use presentation.
- A device or container system that reduces dose loss.
- A clinically meaningful administration advantage.
- A narrow pediatric formulation with a distinct technical effect.
Even these positions would face obviousness, enablement, written-description, and freedom-to-operate challenges. A commercial program should prioritize regulatory execution and supply reliability over speculative excipient patenting.
Key Takeaways
- Clolar uses a simple aqueous formulation containing clofarabine, sodium chloride, and water for injection.
- The product is preservative-free and supplied as a single-dose intravenous vial.
- The lowest-risk generic strategy is to replicate the reference formulation and container system.
- The primary technical risks are chemical stability, impurities, dilution compatibility, and container-closure performance.
- Clofarabine has no biosimilar risk because it is a small molecule.
- Historical compound and orphan exclusivity periods have expired.
- Current patent risk depends on Orange Book listings and any surviving formulation, method-of-use, process, or device claims.
- Commercial opportunities are strongest in generic sterile supply, pediatric vial optimization, ready-to-dilute presentations, and hospital procurement agreements.
- Novel excipient claims are less attractive than formulation-process, packaging, and delivery-system claims.
- Market size and sterile manufacturing economics are likely to constrain the number of viable entrants.
FAQs
Can clofarabine be formulated without sodium chloride?
Yes, but removing sodium chloride would require a suitable alternative tonicity strategy and comparative stability and compatibility data. The reference formulation uses sodium chloride, making it the lowest-risk benchmark for a generic product.
Is clofarabine available as an oral dosage form?
The approved Clolar product is an intravenous formulation. An oral clofarabine product would require a separate development program involving bioavailability, absorption, food effect, stability, and clinical bridging.
Can a company patent a new clofarabine excipient combination?
Potentially, but a patent would need a novel and non-obvious combination with a defensible technical effect, such as improved stability, reduced impurities, or enhanced administration performance. Conventional use of sodium chloride, water, hydrochloric acid, or sodium hydroxide is unlikely to provide broad exclusivity.
Would a prefilled clofarabine syringe have commercial value?
It could reduce pharmacy preparation steps, but the opportunity is limited by pediatric dose variability, syringe compatibility, stability after filling, low market volume, and the need to validate dose recovery and extractables.
Does clofarabine require a biosimilar development program?
No. Clofarabine is a chemically synthesized small molecule. A competing product would generally pursue an ANDA or, for a materially different formulation or presentation, a 505(b)(2) application.
References
- U.S. Food and Drug Administration. (2006). Clolar (clofarabine) injection prescribing information.
- U.S. Food and Drug Administration. (2017). Quality considerations for clinical pharmacology studies involving therapeutic proteins. FDA.
- U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
- U.S. Food and Drug Administration. (2024). Orphan drug designations and approvals database. FDA.
- U.S. Food and Drug Administration. (2023). Abbreviated new drug application submissions: Refuse-to-receive standards. FDA.
